Molbio Diagnostics IPO Day 2 Subscription Status: 3.11x Subscribed; GMP at ₹122
Molbio Diagnostics’ IPO was subscribed 3.11 times on Day 2, led by Non-Institutional Investors (NIIs) at 5.21 times. Retail demand reached 3.18 times, while Qualified Institutional Buyers (QIBs) subscribed 1.39 times. The Grey Market Premium (GMP) stood at ₹122 as of early evening (5:00 p.m. to 6:29 p.m. IST) on 11 August 2026. The issue remains open and closes on 12 August 2026.
| Metric | Latest update |
| Bidding day | Day 2 |
| Data status | Early evening on 11 August 2026 |
| Overall subscription | 3.11x |
| QIB subscription | 1.39x |
| NII subscription | 5.21x |
| Retail subscription | 3.18x |
| Employee subscription | 4.78x |
| Current GMP | ₹122 |
| GMP percentage | 15.1% |
| Indicative price | ₹929 |
| Closing date | 12 August 2026 |
Molbio Diagnostics IPO Day 2 Subscription Status
The latest bidding data showed demand for about 2.54 crore shares against roughly 81.59 lakh shares available, taking the overall subscription to 3.11 times.
| Investor category | Day 2 | Day 1 close | Change |
| Qualified Institutional Buyers | 1.39x | 1.00x | +0.39x |
| Non-Institutional Investors | 5.21x | 0.73x | +4.48x |
| Retail Individual Investors | 3.18x | 0.77x | +2.41x |
| Employees | 4.78x | Not separately available | N/A |
| Overall | 3.11x | 0.83x | +2.28x |
NIIs recorded the highest multiple among the main investor categories, while retail and QIB portions were also fully subscribed by the latest Day 2 update.
Subscription multiples measure the quantity of shares bid for relative to shares reserved in each category. They do not represent the number of unique applicants.
How Subscription Changed From Day 1
Molbio Diagnostics IPO closed Day 1 at 0.83 times overall, with QIBs at 1.00 times, NIIs at 0.73 times, and retail investors at 0.77 times.
By early evening on Day 2, the overall book had risen by 2.28 times to 3.11 times. The strongest acceleration came from NIIs, whose subscription increased from 0.73 times to 5.21 times.
Retail demand also strengthened to 3.18 times, while QIB participation rose more gradually to 1.39 times. This indicates that demand became broader on Day 2 rather than depending entirely on a single investor category.
Molbio Diagnostics IPO GMP Today and Estimated Listing Price
Molbio Diagnostics IPO GMP stood at ₹122 as of early evening on 11 August 2026, compared with the previous available reading of ₹127 on 10 August 2026.
| GMP observation | GMP | Movement |
| 11 August 2026, early evening | ₹122 | Down ₹5 |
| 10 August 2026 | ₹127 | Previous reading |
At the upper price band of ₹807, the current GMP implies:
Indicative price = ₹807 + ₹122 = ₹929
GMP percentage = ₹122 ÷ ₹807 × 100 = 15.1%
The ₹929 figure is only an indicative grey-market estimate. GMP is unofficial and unregulated, can change quickly, and does not guarantee the actual listing price or any listing gain.
What Stands Out in Today’s Bidding
Two points stand out from the Day 2 data.
First, overall subscription increased from 0.83 times at the end of Day 1 to 3.11 times on Day 2, with NIIs contributing the strongest category-level increase.
Second, retail and QIB demand also moved above one time. This makes the subscription profile broader than it was on the opening day.
There are important limitations. Subscription multiples reflect bid quantity relative to category allocation, not the number of unique investors. A smaller reserved category can also reach a high multiple more quickly.
GMP also slipped from ₹127 to ₹122 even as subscription strengthened. This divergence shows why subscription and GMP should be read as separate signals. Neither establishes fair valuation, business quality, listing gains, or long-term returns.
IPO Details Retail Investors Need
| Detail | Molbio Diagnostics IPO |
| Price band | ₹768 to ₹807 per share |
| Lot size | 18 shares |
| Minimum retail investment | ₹14,526 |
| Issue size | ₹939.70 crore |
| Fresh issue | ₹200 crore |
| Offer for Sale (OFS) | ₹739.70 crore |
| Issue type | Mainboard book-built IPO |
| Closing date | 12 August 2026 |
| Expected listing date | 17 August 2026 |
| Exchange | BSE and NSE |
At the upper price band of ₹807, one lot of 18 shares requires a minimum retail investment of ₹14,526.
Brief Company and Financial Context
Molbio Diagnostics develops point-of-care molecular diagnostic products, with its Truenat platform and disease-specific test kits forming an important part of its business. Revenue from operations rose to ₹1,445.69 crore in FY2026 from ₹1,020.42 crore in FY2025, while restated profit increased to ₹164.14 crore from ₹138.58 crore.
Fresh-issue proceeds are intended mainly for research and development infrastructure, a Centre of Excellence, and manufacturing equipment. One material risk is customer concentration, as government bodies and international aid agencies account for a significant share of finished-goods product revenue.
What Happens Next
Molbio Diagnostics IPO enters its Closing Day on 12 August 2026. The main points to monitor are whether QIB participation accelerates, whether NII and retail demand continues to build, and whether the GMP stabilises or changes further.
Day 2 subscription figures are interim and do not indicate where the final subscription multiple will settle.
Frequently Asked Questions (FAQs)
Q: How many times was the Molbio Diagnostics IPO subscribed on Day 2?
A: Molbio Diagnostics IPO was subscribed 3.11 times as of early evening on 11 August 2026. NIIs led at 5.21 times, retail investors subscribed 3.18 times, and QIBs subscribed 1.39 times.
Q: What is the Molbio Diagnostics IPO GMP today?
A: The latest tracked Molbio Diagnostics IPO GMP was ₹122 as of early evening on 11 August 2026. The previous available reading was ₹127, meaning the GMP was down by ₹5.
Q: What listing price does the current Molbio Diagnostics IPO GMP indicate?
A: At the upper price band of ₹807 and a GMP of ₹122, the indicative price works out to ₹929 per share. This is only a grey-market estimate and is not a guaranteed listing price.
Q: Does high Molbio Diagnostics IPO subscription guarantee a premium listing?
A: No. High subscription shows strong bidding demand, but it does not guarantee a premium listing. Listing performance can also depend on valuation, overall market conditions, company fundamentals, and investor sentiment, while GMP itself is unofficial.
Disclaimer
The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.
